Overall, 5.8% of patients developed the new cancers. Four of the trials compared outcomes for patients who received CAR-T therapy versus standard regimens. Rates of secondary cancers were similar ...

We preselected all newsletters you had before unsubscribing.

Researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients. This discovery has fueled new strategies that ...

CAR-T Therapy Won't Raise Odds for a Second Cancer, Study Finds By Ernie Mundell HealthDay Reporter WEDNESDAY, Sept. 11, 2024 (HealthDay News) -- Contrary to a warning placed on labels for CART-T ...

According to the American Cancer Society, in CAR-T therapy, immune system T-cells "are taken from the patient's blood and are changed in the lab by adding a gene for a receptor (called a ...

Overall, 5.8% of patients developed the new cancers. Four of the trials compared outcomes for patients who received CAR-T therapy versus standard regimens. Rates of secondary cancers were similar ...

When the symptoms and inflammation are not brought under control, they can cause organ damage. Like other cell therapies, CAR T cell therapy uses a modified cell either from the patient or from a ...

The probe is directed at all CAR-Ts currently ... positive lymphoma – in patients who had received both types of CAR-T therapy. The regulator highlighted the products by name, including Bristol- ...

Chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, is one type of immunotherapy. Sometimes likened to a “smart drug” or “living drug,” CAR-T cell therapy relies on ...

Bottom Line: The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs ...

An interview with Anusha Kalbasi, MD, a radiation oncologist who studies CAR-T therapy to treat advanced melanoma, a type of ...